Akero Therapeutics (AKRO) Company Report

Akero Therapeutics, Inc. stockholders approved the company's pending acquisition by Novo Nordisk A/S at a special meeting held virtually on December 2, 2025.
The Merger Proposal was approved with 66,887,600 votes For, and the advisory, non-binding Compensation Proposal was also approved.
The U.S. Federal Trade Commission (FTC) granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on December 2, 2025, satisfying one of the conditions for closing.
The parties expect the merger to close by around year-end 2025, subject to the satisfaction or waiver of other customary closing conditions.

1 day ago

8-K

Akero Therapeutics Stockholders Approve Merger with Novo Nordisk

AKRO

M&A

Proxy Vote Outcomes

Executive Compensation

Akero Therapeutics held a special meeting of stockholders on December 2, 2025, with a quorum present based on the record date of November 7, 2025.
Stockholders approved the merger proposal, which involves Akero becoming a wholly owned subsidiary of Novo Nordisk A/S, as outlined in the Agreement and Plan of Merger dated October 9, 2025.
An advisory non-binding proposal regarding the payment of certain compensation to Akero's named executive officers in connection with the merger was also approved by stockholders.

3 days ago

Transcript

Akero Stockholders Approve Merger with Novo Nordisk

AKRO

M&A

Proxy Vote Outcomes

Executive Compensation

Akero Therapeutics Inc. held a special meeting of stockholders on December 2, 2025, with a record date of November 7, 2025.
Stockholders approved the Agreement and Plan of Merger dated October 9, 2025, by and among Akero, Novo Nordisk A/S, and NN Invest Sub Incorporated.
As a result of the merger, NN Invest Sub Incorporated will merge with and into Akero, with Akero surviving as a wholly owned subsidiary of Novo Nordisk.
An advisory non-binding proposal for the payment of certain compensation to Akero's named executive officers in connection with the merger was also approved.

3 days ago

Transcript

Akero Stockholders Approve Merger with Novo Nordisk

AKRO

M&A

Proxy Vote Outcomes

Executive Compensation

Akero Therapeutics' stockholders approved the Agreement and Plan of Merger with Novo Nordisk A/S and NN Invest Sub Incorporated at a special meeting held on December 2, 2025.
As a result of the merger, Akero will survive as a wholly owned subsidiary of Novo Nordisk.
An advisory non-binding proposal regarding executive compensation payable in connection with the merger was also approved by stockholders.

3 days ago

Transcript

Akari Therapeutics Presents Positive Preclinical Immuno-Oncology Data for Novel ADC Payload PH1

AKRO

New Projects/Investments

Akari Therapeutics presented positive preclinical immuno-oncology data for its novel spliceosome-targeting ADC payload, PH1, at the 40th Annual SITC Meeting on November 10, 2025.
The PH1 payload demonstrated the ability to induce cancer cell cytotoxicity and activate anti-tumor immunity through multiple mechanisms, including macrophage polarization and B cell clone expansion.
In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 therapy achieved a 74% complete response rate, statistically outperforming Kadcyla® + anti-PD1, which showed a 42% complete response rate (p <0.05).
This data highlights the synergy between the PH1 payload and checkpoint inhibitors, with the potential to expand the immuno-oncology therapeutic class.
Akari is initiating IND-enabling studies for its lead candidate, AKTX-101 (a Trop2 PH1 ADC), with plans to advance it into clinical trials.

Nov 10, 2025, 1:30 PM

Press Release

Akero Therapeutics Announces New Phase 2b Trial Findings for Efruxifermin

AKRO

New Projects/Investments

Akero Therapeutics announced new findings from its Phase 2b SYMMETRY and HARMONY trials of efruxifermin, which will be presented at the 76th Annual AASLD The Liver Meeting® 2025 from November 7-11, 2025.
Post-hoc analyses of 96-week SYMMETRY trial data indicated efruxifermin was associated with statistically significant improvements in clinically significant portal hypertension (CSPH) risk and corroborated antifibrotic effects in patients with compensated cirrhosis (F4c) due to MASH.
AI-powered digital pathology analyses from both the SYMMETRY and HARMONY trials reinforced previously reported fibrosis improvements in patients with F4c MASH and F2/F3 MASH, respectively.
These results support the potential of efruxifermin as a therapeutic option for MASH, with validation ongoing in the Phase 3 SYNCHRONY clinical trial program.

Nov 7, 2025, 12:00 PM

Press Release

Akero Therapeutics Acquisition Announced with Shareholder Investigation

AKRO

M&A

Legal Proceedings

Takeover Bid

Akero Therapeutics, Inc. (Nasdaq - AKRO) is set to be acquired by Novo Nordisk A/S.
Shareholders will receive $54.00 per share in cash at closing.
An additional $6.00 per share Contingent Value Right (CVR) is included, contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis due to MASH by June 30, 2031.
A legal investigation is underway concerning whether the Akero Board breached its fiduciary duties and if the deal consideration provides fair value to shareholders.

Oct 16, 2025, 8:51 PM

Press Release

Akero Therapeutics to be Acquired by Novo Nordisk

AKRO

M&A

Takeover Bid

Akero Therapeutics, Inc. has entered into a definitive agreement to be acquired by Novo Nordisk A/S for up to $5.2 billion in cash.
Akero shareholders will receive $54.00 per share in cash at closing and a non-transferable Contingent Value Right (CVR) of $6.00 per share upon full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis due to MASH by June 30, 2031.
The upfront cash portion of the consideration, approximately $4.7 billion, represents a 19% premium to Akero's 30-day Volume Weighted Average Price (VWAP).
The transaction has been unanimously approved by Akero's Board of Directors and is expected to close around year-end, subject to shareholder and regulatory approvals.

Oct 9, 2025, 8:31 PM

8-K

Akero Therapeutics under investigation by Ademi Firm regarding Novo Nordisk transaction

AKRO

Legal Proceedings

M&A

Takeover Bid

The Ademi Firm is investigating Akero Therapeutics (NASDAQ: AKRO) for potential breaches of fiduciary duty and other legal violations concerning its transaction with Novo Nordisk.
Akero shareholders are set to receive $54.00 per share, representing an equity value of approximately $4.7 billion.
Shareholders will also receive a contingent value right entitling them to an additional $6.00 per share if Akero's drug efruxifermin receives full U.S. regulatory approval for treating compensated cirrhosis due to MASH by June 30, 2031.
The investigation also focuses on the conduct of Akero's board of directors, specifically regarding change of control arrangements benefiting insiders and a significant penalty that limits competing bids.

Oct 9, 2025, 3:00 PM

Press Release

Akero Therapeutics to be Acquired by Novo Nordisk

AKRO

M&A

Takeover Bid

New Projects/Investments

Akero Therapeutics has entered into a definitive agreement to be acquired by Novo Nordisk A/S for up to $5.2 billion in cash.
Akero shareholders will receive $54.00 per share in cash at closing and a Contingent Value Right (CVR) of $6.00 per share, contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis due to MASH by June 30, 2031.
The upfront cash portion of the consideration, approximately $4.7 billion, represents a 19% premium to Akero’s 30-day Volume Weighted Average Price (VWAP).
The transaction, unanimously approved by Akero’s Board of Directors, is expected to close around year-end, pending shareholder and regulatory approvals.
Akero’s lead product candidate, efruxifermin (EFX), a treatment for metabolic dysfunction-associated steatohepatitis (MASH), will complement Novo Nordisk’s GLP-1 based metabolic treatments.

Oct 9, 2025, 10:01 AM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Akero Therapeutics.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Andrew Cheng say about margins?What are Akero Therapeutics's strategic priorities?How is Akero Therapeutics positioned vs competitors?How did Akero Therapeutics do last quarter?

Let Fintool AI Agent track Akero Therapeutics's earnings for you

Get instant analysis when filings drop